



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hiroshi MIURA, et al.

SERIAL NO: 10/554,921

GAU:

FILED: October 31, 2005

EXAMINER:

FOR: COMPOSITION CONTAINING MEDICINE EXTREMELY SLIGHTLY SOLUBLE IN WATER BEING EXCELLENT IN ELUTING PROPERTY AND METHOD FOR PREPARATION THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☒ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided: Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, MCCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 280271US0X PCT		SERIAL NO. 10/554,921	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hiroshi MIURA, et al.			
				FILING DATE October 31, 2005		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	6 348 468	02/19/02	Masao OHKUCHI et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AK	2002-345940	12/03/02	JP(English abstract only)			NO
	AL	61-227520	10/09/86	JP(English abstract only)			NO
	AM	6-040714	02/15/94	JP(English abstract only)			NO
	AN	2000-198776	07/18/00	JP(English abstract only)			NO
	AO	02/051381	07/04/02	WO(abstract only)			NO
	AP	02/20624	03/14/02	WO			NO
	AQ	02/060411	08/08/02	WO			NO
	AR	2000-198776	07/18/00	JP(English abstract only, equivalent of US 6348468)			NO
	AS	2002-302435	10/18/02	JP(English abstract only, equivalent of US 2004/52854, & US 2005/232954)			NO
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	David D. HILE, et al., "Active growth factor delivery from poly(D,L-lactide-co-glycolide) foams prepared in supercritical CO <sub>2</sub> ", JOURNAL OF CONTROLLED RELEASE, vol. 66, pages 177-185 2000					
	AX	Petra SENCAR-BOZIC, et al., "Improvement of nifedipine dissolution characteristics using supercritical CO <sub>2</sub> ", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 148, pages 123-130 1997					
	AY						
	AZ						<input type="checkbox"/> Additional References sheet(s) attached
Examiner /Jeffrey Palenik/					Date Considered 04/03/2008		

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. PCT Application Serial No: 10/554,921

Filed: October 31, 2005

Hiroshi MIURA, et al.

Docket No. 280271US0XPCT

#### STATEMENT OF RELEVANCY

- 1) References AK-AQ, & AW-AX have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References            have been cited in the corresponding            Search Report. A copy of these references is being submitted herewith.
- 3) References AR & AS are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References            are additional prior art known to Applicant. A copy of these references is being submitted herewith.



LIST OF RELATED CASES CITED BY  
APPLICANT UNDER 37 CFR 1.56

Docket No.: 280271US0X PCT

Serial No.: 10/554,921

Inventor: Hiroshi MIURA, et al.

Filing Date: October 31, 2005

Group:

**LIST OF RELATED CASES**

<u>Examiner Initial</u>	<u>Docket No.</u>	<u>Serial or Patent Number</u>	<u>Filing or Issue Date</u>	<u>Patent App. Publication No.</u>	<u>Inventor or Applicant</u>
	277987US0PCT	10/551,901	10/04/05		MIURA, et al.
	280271US0XPCT*	10/554,921	10/31/05		MIURA, et al.
	0080-0086-0PCT	6,348,468	02/19/02		OHKUCHI, et al.

Examiner /Jeffrey Palenik/

Date Considered

04/03/2008

\*Present Application; listed for information  
NFO/kch/hah

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./